Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis
Shots:
- Imcyse to receive up front- ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse
- Initially- the companies will collaborate to develop existing lead candidates and further optimize potential molecules. Later- Pfizer will lead clinical development and commercialization activities for the program
- The Imotope platform is a curative approach to severe autoimmune diseases. Imcyse plan to initiate a P-II study with its lead candidate in T1D and MS in 2022
Ref: Accesswire | Image: Imcyse
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com